{
  "id": "5884fed0e56acf5176000011",
  "type": "summary",
  "question": "What is the mechanism of action of Pictilisib?",
  "ideal_answer": "Pictilisib acts by inhibiting PI3K. It is used for breast cancer treatment.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/27044711",
    "http://www.ncbi.nlm.nih.gov/pubmed/25370471",
    "http://www.ncbi.nlm.nih.gov/pubmed/27573562",
    "http://www.ncbi.nlm.nih.gov/pubmed/26830312",
    "http://www.ncbi.nlm.nih.gov/pubmed/27565810",
    "http://www.ncbi.nlm.nih.gov/pubmed/26733612",
    "http://www.ncbi.nlm.nih.gov/pubmed/26965285",
    "http://www.ncbi.nlm.nih.gov/pubmed/27489350",
    "http://www.ncbi.nlm.nih.gov/pubmed/27012832",
    "http://www.ncbi.nlm.nih.gov/pubmed/24754926",
    "http://www.ncbi.nlm.nih.gov/pubmed/27155741",
    "http://www.ncbi.nlm.nih.gov/pubmed/27048952",
    "http://www.ncbi.nlm.nih.gov/pubmed/27529512",
    "http://www.ncbi.nlm.nih.gov/pubmed/26976426"
  ],
  "snippets": [
    {
      "text": "EXPERIMENTAL DESIGN: Antiestrogen-sensitive and antiestrogen-resistant ER(+) human breast cancer cell lines and mice bearing PIK3CA-mutant xenografts were treated with the antiestrogen fulvestrant, the PI3K inhibitor GDC-0941 (pictilisib; varied doses/schedules that provided similar amounts of drug each week), or combinations. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26733612",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "These strategies include first-line therapy with high-dose fulvestrant or everolimus (in combination with exemestane or letrozole or with other endocrine therapies), use of the PI3K inhibitors (e.g., buparlisib, alpelisib, pictilisib, taselisib), entinostat, CDK 4/6 inhibitors (e.g., palbociclib, ribociclib, abemaciclib), and novel selective estrogen receptor degradation agents that may enhance the targeting of acquired mutations in the ESR1 gene.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26830312",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Phase II Randomized Preoperative Window-of-Opportunity Study of the PI3K Inhibitor Pictilisib Plus Anastrozole Compared With Anastrozole Alone in Patients With Estrogen Receptor-Positive Breast Cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26976426",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "This preoperative window study assessed whether adding the PI3K inhibitor pictilisib (GDC-0941) can increase the antitumor effects of anastrozole in primary breast cancer and aimed to identify the most appropriate patient population for combination therapy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26976426",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In contrast to parental cells, resistant cells were sensitive to growth inhibition and apoptosis induced by the class I PI3K inhibitor, GDC-0941 (pictilisib), which also induced FOXO1 nuclear translocation.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27044711",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Using a mass spectrometry-based metabolomics platform, we discovered that plasma concentrations of 26 metabolites, including amino acids, acylcarnitines, and phosphatidylcholines, were decreased in mice bearing PTEN-deficient tumors compared with non-tumor-bearing controls and in addition were increased following dosing with class I PI3K inhibitor pictilisib (GDC-0941).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27048952",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The PI3K inhibitor pictilisib plus anastrozole suppresses luminal B breast cancer proliferation.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27012832",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Pictilisib is an oral inhibitor of multiple PI3K isoforms.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27155741",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Pictilisib (GDC-0941) is an oral class I phosphatidylinositol-3-phosphate kinase inhibitor.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27565810",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Distribution of the phosphatidylinositol 3-kinase inhibitors Pictilisib (GDC-0941) and GNE-317 in U87 and GS2 intracranial glioblastoma models-assessment by matrix-assisted laser desorption ionization imaging.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24754926",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25370471",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "PURPOSE: This first-in-human dose-escalation trial evaluated the safety, tolerability, maximal-tolerated dose (MTD), dose-limiting toxicities (DLT), pharmacokinetics, pharmacodynamics, and preliminary clinical activity of pictilisib (GDC-0941), an oral, potent, and selective inhibitor of the class I phosphatidylinositol-3-kinases (PI3K).PATIENTS AND METHODS: Sixty patients with solid tumors received pictilisib at 14 dose levels from 15 to 450 mg once-daily, initially on days 1 to 21 every 28 days and later, using continuous dosing for selected dose levels. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25370471",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The PI3K inhibitor pictilisib plus anastrozole suppresses luminal B breast cancer proliferation. <CopyrightInformation>\u00a92016 American Association for Cancer Research.</C",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27012832",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Understanding the temporal response and pharmacodynamic effects of PI3K inhibition in ER(+) breast cancer will provide a rationale for treatment scheduling to maximize therapeutic index.Antiestrogen-sensitive and antiestrogen-resistant ER(+) human breast cancer cell lines and mice bearing PIK3CA-mutant xenografts were treated with the antiestrogen fulvestrant, the PI3K inhibitor GDC-0941 (pictilisib; varied doses/schedules that provided similar amounts of drug each week), or combinations.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26733612",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The objectives of these studies were to visualize and compare by matrix-assisted laser desorption ionization (MALDI) imaging mass spectrometry the brain and tumor distribution of the phosphatidylinositol 3-kinase (PI3K) inhibitors pictilisib (GDC-0941, 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine) and GNE-317 [5-(6-(3-methoxyoxetan-3-yl)-7-methyl-4-morpholinothieno[3,2-d]pyrimidin-2-yl)pyrimidin-2-amine] in U87 and GS2 orthotopic models of GBM, models that exhibit differing blood-brain barrier characteristics.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24754926",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Treating Mx1-Cre, Kras(D12) mice with GDC-0941 (also referred to as pictilisib), an orally bioavailable inhibitor of class I PI3K isoforms, reduced leukocytosis, anemia and splenomegaly while extending survival.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26965285",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "These strategies include first-line therapy with high-dose fulvestrant or everolimus (in combination with exemestane or letrozole or with other endocrine therapies), use of the PI3K inhibitors (e.g., buparlisib, alpelisib, pictilisib, taselisib), entinostat, CDK 4/6 inhibitors (e.g., palbociclib, ribociclib, abemaciclib), and novel selective estrogen receptor degradation agents that may enhance the targeting of acquired mutations in the ESR1 gene. <CopyrightInformation>Copyright \u00a9 2015.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26830312",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Pictilisib is an oral inhibitor of multiple PI3K isoforms.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27155741",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [
    "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020228"
  ]
}